{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:14:25Z","timestamp":1792134865639,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>We aimed to evaluate the prevalence of incidental <jats:sup>68<\/jats:sup>\u00a0Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET\/CT (SSTR PET\/CT) findings, their clinical significance in the need for follow-up, and their risk of malignancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Studies reporting incidental SSTR PET\/CT findings were systematically searched in PubMed, Cochrane, Embase and Web of Science literature published prior to 1<jats:sup>st<\/jats:sup> of May 2020. Studies were filtered by two independent readers for eligibility based on title and abstract, and subsequently on full text. The main exclusion criteria were: 1) pathological findings that matched scan indication, 2) known organ specific disease and\/or incidental findings confirmed on other scan modality prior to SSTR PET\/CT, 3) lack of diagnosis and\/or follow up, and 4) results published in proceedings or conference abstracts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-one studies, comprising a total of 2906 subjects, were eligible for the analysis. Studies included were retrospective cohort studies on incidental SSTR PET\/CT findings in a specific organ (<jats:italic>n<\/jats:italic>\u2009=\u20092888, 7\/21) or case reports (<jats:italic>n<\/jats:italic>\u2009=\u200918, 14\/21). A total of 133 subjects had incidental SSTR PET\/CT findings. Incidental findings were predominantly seen in the thyroid gland (<jats:italic>n<\/jats:italic>\u2009=\u200965), spine (<jats:italic>n<\/jats:italic>\u2009=\u200930), brain (<jats:italic>n<\/jats:italic>\u2009=\u200926) and breast (<jats:italic>n<\/jats:italic>\u2009=\u20096). Seventeen of 133 (13%) incidental findings were malignant on final diagnosis. Incidental breast findings were associated with the highest risk of malignancy (67%). In the thyroid, incidental SSTR uptake was caused by malignancy in 8%, all presenting as focal uptake. The lowest risk was seen in the spine with a malignancy rate of 3% in patients with incidental SSTR uptake and benign cases were interpreted as vertebral hemangiomas on CT. Incidental SSTR PET\/CT findings in other locations were of malignant etiology in two out of six cases (33%) and should be evaluated individually.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The most incidental SSTR PET\/CT findings were found in the thyroid gland, spine, and brain. The risk of malignancy was greatest in incidental SSTR PET\/CT findings in the breast, cranially, and thyroid gland. The results of the present study can prove useful in the interpretation of atypical findings on SSTR PET\/CT and in the counseling of clinicians.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40644-022-00484-0","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T16:02:49Z","timestamp":1662220969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prevalence and significance of incidental findings on 68\u00a0Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET\/CT: a systematic review of the literature"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-0967","authenticated-orcid":false,"given":"Morten","family":"Bentestuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Gossili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Elberling","family":"Almasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle Damgaard","family":"Zacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"issue":"3","key":"484_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34(3):228\u201352.","journal-title":"Front Neuroendocrinol"},{"issue":"14","key":"484_CR2","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.2217\/fon.14.139","volume":"10","author":"CB Johnbeck","year":"2014","unstructured":"Johnbeck CB, Knigge U, Kjaer A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10(14):2259\u201377.","journal-title":"Future Oncol"},{"issue":"2","key":"484_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2214\/AJR.18.19881","volume":"211","author":"Y Sanli","year":"2018","unstructured":"Sanli Y, et al. Neuroendocrine Tumor Diagnosis and Management: (68)Ga-DOTATATE PET\/CT. AJR Am J Roentgenol. 2018;211(2):267\u201377.","journal-title":"AJR Am J Roentgenol"},{"key":"484_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.clinimag.2020.05.035","volume":"67","author":"L Evangelista","year":"2020","unstructured":"Evangelista L, et al. Ga-68 DOTA-peptides and F-18 FDG PET\/CT in patients with neuroendocrine tumor: a review. Clin Imaging. 2020;67:113\u20136.","journal-title":"Clin Imaging"},{"issue":"1","key":"484_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12020-012-9631-1","volume":"42","author":"G Treglia","year":"2012","unstructured":"Treglia G, et al. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET\/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42(1):80\u20137.","journal-title":"Endocrine"},{"issue":"11","key":"484_CR6","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1007\/s00259-016-3395-4","volume":"43","author":"I Virgolini","year":"2016","unstructured":"Virgolini I, et al. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2016;43(11):2072\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"484_CR7","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1097\/RLU.0b013e31825b2555","volume":"37","author":"J Kunikowska","year":"2012","unstructured":"Kunikowska J, et al. Semiquantitative analysis and characterization of physiological biodistribution of (68)Ga-DOTA-TATE PET\/CT. Clin Nucl Med. 2012;37(11):1052\u20137.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"484_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s12149-013-0718-4","volume":"27","author":"S Kuyumcu","year":"2013","unstructured":"Kuyumcu S, et al. Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med. 2013;27(6):538\u201345.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"484_CR9","first-page":"61","volume":"54","author":"V Prasad","year":"2010","unstructured":"Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010;54(1):61\u20137.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"4","key":"484_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00259-012-2309-3","volume":"40","author":"A Kroiss","year":"2013","unstructured":"Kroiss A, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET\/CT. Eur J Nucl Med Mol Imaging. 2013;40(4):514\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"484_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5603\/EP.2015.0030","volume":"66","author":"J Kunikowska","year":"2015","unstructured":"Kunikowska J, et al. How often do we see incidental 68Ga-DOTATATE thyroid uptake in PET\/CT in patients with neuroendocrine tumours? Endokrynol Pol. 2015;66(3):231\u20136.","journal-title":"Endokrynol Pol"},{"issue":"6","key":"484_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1089\/thy.2016.0174","volume":"26","author":"P Nockel","year":"2016","unstructured":"Nockel P, et al. The rate and clinical significance of incidental thyroid uptake as detected by gallium-68 DOTATATE positron emission tomography\/computed tomography. Thyroid. 2016;26(6):831\u20135.","journal-title":"Thyroid"},{"key":"484_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535.","journal-title":"BMJ"},{"issue":"2","key":"484_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/RLU.0000000000001950","volume":"43","author":"S Mahajan","year":"2018","unstructured":"Mahajan S, Shaha A, Grewal RK. Incidental detection of medullary thyroid carcinoma by 68Ga-DOTATATE PET\/CT in a patient with neuroendocrine tumor liver metastases. Clin Nucl Med. 2018;43(2):136\u20138.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"484_CR15","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1097\/RLU.0000000000001620","volume":"42","author":"LYI Yamaga","year":"2017","unstructured":"Yamaga LYI, Wagner J, Funari MBG. 68Ga-DOTATATE PET\/CT in nonneuroendocrine tumors: a pictorial essay. Clin Nucl Med. 2017;42(6):e313\u20136.","journal-title":"Clin Nucl Med"},{"issue":"11","key":"484_CR16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/RLU.0000000000001356","volume":"41","author":"M Chan","year":"2016","unstructured":"Chan M, Hsiao E. Incidental finding of cerebellar medulloblastoma on 68Ga-DOTATATE PET\/CT in a patient with appendiceal carcinoid. Clin Nucl Med. 2016;41(11):886\u20137.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"484_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/wjnm.wjnm_39_18","volume":"18","author":"RV Parghane","year":"2019","unstructured":"Parghane RV, Talole S, Basu S. Prevalence of hitherto unknown brain meningioma detected on (68)Ga-DOTATATE positron-emission tomography\/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of (177)Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors. World J Nucl Med. 2019;18(2):160\u201370.","journal-title":"World J Nucl Med"},{"key":"484_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clineuro.2016.02.028","volume":"144","author":"A Lasocki","year":"2016","unstructured":"Lasocki A, et al. Cerebellar haemangioblastoma discovered incidentally on (68)Ga-DOTA-octreotate examination. Clin Neurol Neurosurg. 2016;144:20\u20132.","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"484_CR19","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/1754-9485.12069","volume":"57","author":"WP Law","year":"2013","unstructured":"Law WP, et al. The \u2018double pituitary hot spot\u2019 sign of skull base meningioma on gallium-68-labelled somatostatin analogue PET. J Med Imaging Radiat Oncol. 2013;57(6):680\u20133.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"11","key":"484_CR20","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1097\/MNM.0000000000000571","volume":"37","author":"JO Cleary","year":"2016","unstructured":"Cleary JO, et al. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients. Nucl Med Commun. 2016;37(11):1197\u2013205.","journal-title":"Nucl Med Commun"},{"issue":"36","key":"484_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011878","volume":"97","author":"T Sampaio Vieira","year":"2018","unstructured":"Sampaio Vieira T, et al. Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography\/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: a case report. Medicine (Baltimore). 2018;97(36): e11878.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"484_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3413\/nukmed-0185","volume":"47","author":"F Elgeti","year":"2008","unstructured":"Elgeti F, et al. Incidental detection of breast cancer by 68Ga-DOTATOC-PET\/CT in women suffering from neuroendocrine tumours. Nuklearmedizin. 2008;47(6):261\u20135.","journal-title":"Nuklearmedizin"},{"issue":"10","key":"484_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/RLU.0000000000002597","volume":"44","author":"V Pandika","year":"2019","unstructured":"Pandika V, Covington MF. Incidental uptake in Benign Gynecomastia on 68Ga-DOTATATE PET\/CT. Clin Nucl Med. 2019;44(10):799\u2013800.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"484_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4274\/mirt.93064","volume":"25","author":"D Has \u015eim\u015fek","year":"2016","unstructured":"Has \u015eim\u015fek D, et al. An incidental solitary plasmacytoma of bone mimicking neuroendocrine tumor metastasis on 68Ga-DOTATATE positron emission tomography\/computed tomography. Mol Imaging Radionucl Ther. 2016;25(3):147\u20139.","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"9","key":"484_CR25","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1007\/s00330-017-5294-x","volume":"28","author":"M Gauth\u00e9","year":"2018","unstructured":"Gauth\u00e9 M, et al. Vertebral metastases from neuroendocrine tumours: how to avoid false positives on (68)Ga-DOTA-TOC PET using CT pattern analysis? Eur Radiol. 2018;28(9):3943\u201352.","journal-title":"Eur Radiol"},{"issue":"7","key":"484_CR26","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1097\/RLU.0000000000000779","volume":"40","author":"E Skoura","year":"2015","unstructured":"Skoura E, et al. Adolescent with 68Ga DOTATATE-avid vertebral hemangioma mimicking metastasis in PET imaging. Clin Nucl Med. 2015;40(7):e378\u20139.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"484_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/RLU.0000000000001488","volume":"42","author":"M Vadrucci","year":"2017","unstructured":"Vadrucci M, Vandoni A, Gilardi L. Incidental detection of retiform hemangioendothelioma by 68Ga DOTATOC PET\/CT. Clin Nucl Med. 2017;42(2):149\u201351.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"484_CR28","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/RLU.0000000000002133","volume":"43","author":"ST Laurens","year":"2018","unstructured":"Laurens ST, Netea-Maier RT, Aarntzen EJHG. 68Ga-DOTA-TOC uptake in pleomorphic adenoma. Clin Nucl Med. 2018;43(7):524\u20135.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"484_CR29","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1097\/RLU.0000000000002023","volume":"43","author":"M Ishiyama","year":"2018","unstructured":"Ishiyama M, Vesselle H. 68Ga DOTATATE PET\/CT imaging of elastofibroma dorsi. Clin Nucl Med. 2018;43(5):e154\u20135.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"484_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s12020-019-02179-2","volume":"68","author":"H Liu","year":"2020","unstructured":"Liu H, Zhang W, Chen Y. Incidental 68Ga-DOTATATE uptake in uterine leiomyoma. Endocrine. 2020;68(1):233\u20134.","journal-title":"Endocrine"},{"issue":"3","key":"484_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s13139-018-0520-2","volume":"52","author":"S Arora","year":"2018","unstructured":"Arora S, et al. Incidental detection of parathyroid adenoma on somatostatin receptor PET\/CT and incremental role of (18)F-fluorocholine PET\/CT in MEN1 syndrome. Nucl Med Mol Imaging. 2018;52(3):238\u201342.","journal-title":"Nucl Med Mol Imaging"},{"issue":"3","key":"484_CR32","first-page":"240","volume":"23","author":"F Gossili","year":"2020","unstructured":"Gossili F, Petersen LJ, Zacho HD. The frequency of thyroid incidental findings and risk of malignancy detected by (68)Ga-labeled prostate-specific membrane antigen PET\/CT in prostate cancer. Hell J Nucl Med. 2020;23(3):240\u20135.","journal-title":"Hell J Nucl Med"},{"issue":"9","key":"484_CR33","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1089\/thy.2012.0005","volume":"22","author":"KK Soelberg","year":"2012","unstructured":"Soelberg KK, et al. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid. 2012;22(9):918\u201325.","journal-title":"Thyroid"},{"issue":"3","key":"484_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/diagnostics8030046","volume":"8","author":"N Gedberg","year":"2018","unstructured":"Gedberg N, et al. The frequency of focal thyroid incidental findings and risk of malignancy detected by 18F-fluorodeoxyglucose positron emission tomography in an iodine deficient population. Diagnostics (Basel). 2018;8(3):46.","journal-title":"Diagnostics (Basel)"},{"key":"484_CR35","first-page":"S189","volume":"41","author":"LC Sobral Violante","year":"2014","unstructured":"Sobral Violante LC, et al. Thyroid incidentalomas detected by 68Ga-dotanoc PET\/CT-correlation of clinical findings and maximum standardized value uptake (SUVmax). Eur J Nucl Med Mol Imaging. 2014;41:S189.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"484_CR36","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"3","key":"484_CR37","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2967\/jnumed.117.191916","volume":"59","author":"H Wang","year":"2018","unstructured":"Wang H, et al. PET\/MRI in the diagnosis of hormone-producing pituitary microadenoma: a prospective pilot study. J Nucl Med. 2018;59(3):523\u20138.","journal-title":"J Nucl Med"},{"issue":"3","key":"484_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/cen.14144","volume":"92","author":"A Tj\u00f6rnstrand","year":"2020","unstructured":"Tj\u00f6rnstrand A, et al. Lower (68) Ga-DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland-A proof-of-concept study. Clin Endocrinol (Oxf). 2020;92(3):222\u201331.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"484_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s12020-015-0689-4","volume":"50","author":"P Santhanam","year":"2015","unstructured":"Santhanam P, et al. PET imaging in ectopic Cushing syndrome: a systematic review. Endocrine. 2015;50(2):297\u2013305.","journal-title":"Endocrine"},{"issue":"1","key":"484_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41824-019-0063-5","volume":"3","author":"EM Aarstad","year":"2019","unstructured":"Aarstad EM, et al. Prevalence of focal incidental breast uptake on FDG-PET\/CT and risk of malignancy: a systematic review and meta-analysis. Eur J Hybrid Imaging. 2019;3(1):16.","journal-title":"Eur J Hybrid Imaging"},{"issue":"1","key":"484_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/MNM.0000000000001309","volume":"42","author":"JD Andersen","year":"2021","unstructured":"Andersen JD, Zacho HD, Petersen LJ. The frequency and malignancy rate of incidental focal breast lesions identified by 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2021;42(1):93\u2013100.","journal-title":"Nucl Med Commun"},{"issue":"6","key":"484_CR42","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1097\/RLU.0000000000003012","volume":"45","author":"A Bashir","year":"2020","unstructured":"Bashir A, et al. Pearls and pitfalls in interpretation of 68Ga-DOTATOC PET imaging. Clin Nucl Med. 2020;45(6):e279\u201380.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"484_CR43","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/0284186X.2017.1342864","volume":"57","author":"T Ruuska","year":"2018","unstructured":"Ruuska T, et al. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at (68)Ga-DOTANOC PET\/CT imaging. Acta Oncol. 2018;57(2):283\u20139.","journal-title":"Acta Oncol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-022-00484-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-022-00484-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-022-00484-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T17:07:52Z","timestamp":1662224872000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-022-00484-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1186\/s40644-022-00484-0","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (NA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}